Who is sponsoring NCT05830058?

NCT05830058 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT05830058?

Interventions in NCT05830058: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy.

What condition does NCT05830058 study?

NCT05830058 studies Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma.

Is NCT05830058 still recruiting?

NCT05830058 is currently recruiting now. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT05830058

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Recruiting now Phase 2 Last updated 5 January 2026

What this trial tests

Phase 2 trial testing Biospecimen Collection in Lung Non-Small Cell Carcinoma in 32 participants. Currently enrolling.

Timeline

29 November 2023

Primary endpoint
3 February 2027

3 February 2027

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	29 November 2023
Primary completion	3 February 2027
Estimated completion	3 February 2027
Sites	1 location across United States

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Computed Tomography
Positron Emission Tomography
Questionnaire Administration
Stereotactic Body Radiation Therapy — full drug profile →

Conditions studied

Lung Non-Small Cell Carcinoma — all drugs for Lung Non-Small Cell Carcinoma →
Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →
Melanoma — all drugs for Melanoma →
Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Lung Non-Small Cell Carcinoma or Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. A PET scan is an imaging test that looks at your tissues and organs using a small amount of a radioactive substance. It also checks for cancer and may help find cancer remaining in areas already treated. Using a PET scan for SBRT planning may help increase the dose of radiation given to the most resistant part of the cancer in patients with oligoprogressive NSCLC, melanoma, and RCC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.
Anderson AC, Ho J, Hall ET, Hannan R, et al · · 2024 · cited 4× · PMID 39258792 · DOI 10.1080/14796694.2024.2389769
The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care.
Sindhu KK, Dovey Z, Thompson M, Nehlsen AD, et al · · 2024 · cited 2× · PMID 38633827 · DOI 10.1002/bco2.323

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other recruiting trials for Lung Non-Small Cell Carcinoma

Currently open trials in the same condition.

NCT07216404 — Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer · Phase 2 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07339254 — Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study · recruiting
NCT06983899 — Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell · NA · recruiting
NCT07186699 — Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05830058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05830058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing